Molecular biomarkers in multiple sclerosis

Abstract Multiple sclerosis (MS) is an inflammatory-neurodegenerative disease of the central nervous system presenting with significant inter- and intraindividual heterogeneity. However, the application of clinical and imaging biomarkers is currently not able to allow individual characterization and...

Full description

Bibliographic Details
Main Authors: Tjalf Ziemssen, Katja Akgün, Wolfgang Brück
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Journal of Neuroinflammation
Subjects:
Online Access:https://doi.org/10.1186/s12974-019-1674-2
id doaj-bd7d34bf98db4562bb32589f3fa45762
record_format Article
spelling doaj-bd7d34bf98db4562bb32589f3fa457622020-12-27T12:05:59ZengBMCJournal of Neuroinflammation1742-20942019-12-0116111110.1186/s12974-019-1674-2Molecular biomarkers in multiple sclerosisTjalf Ziemssen0Katja Akgün1Wolfgang Brück2MS center, Center of Clinical Neuroscience, University Clinic Carl-Gustav Carus, Dresden University of TechnologyMS center, Center of Clinical Neuroscience, University Clinic Carl-Gustav Carus, Dresden University of TechnologyInstitute of Neuropathology, University Medical CenterAbstract Multiple sclerosis (MS) is an inflammatory-neurodegenerative disease of the central nervous system presenting with significant inter- and intraindividual heterogeneity. However, the application of clinical and imaging biomarkers is currently not able to allow individual characterization and prediction. Complementary, molecular biomarkers which are easily quantifiable come from the areas of immunology and neurobiology due to the causal pathomechanisms and can excellently complement other disease characteristics. Only a few molecular biomarkers have so far been routinely used in clinical practice as their validation and transfer take a long time. This review describes the characteristics that an ideal MS biomarker should have and the challenges of establishing new biomarkers. In addition, clinically relevant and promising biomarkers from the blood and cerebrospinal fluid are presented which are useful for MS diagnosis and prognosis as well as for the assessment of therapy response and side effects.https://doi.org/10.1186/s12974-019-1674-2Multiple sclerosisMolecular biomarkerOligoclonal bandsNeurofilamentCerebrospinal fluidTreatment response
collection DOAJ
language English
format Article
sources DOAJ
author Tjalf Ziemssen
Katja Akgün
Wolfgang Brück
spellingShingle Tjalf Ziemssen
Katja Akgün
Wolfgang Brück
Molecular biomarkers in multiple sclerosis
Journal of Neuroinflammation
Multiple sclerosis
Molecular biomarker
Oligoclonal bands
Neurofilament
Cerebrospinal fluid
Treatment response
author_facet Tjalf Ziemssen
Katja Akgün
Wolfgang Brück
author_sort Tjalf Ziemssen
title Molecular biomarkers in multiple sclerosis
title_short Molecular biomarkers in multiple sclerosis
title_full Molecular biomarkers in multiple sclerosis
title_fullStr Molecular biomarkers in multiple sclerosis
title_full_unstemmed Molecular biomarkers in multiple sclerosis
title_sort molecular biomarkers in multiple sclerosis
publisher BMC
series Journal of Neuroinflammation
issn 1742-2094
publishDate 2019-12-01
description Abstract Multiple sclerosis (MS) is an inflammatory-neurodegenerative disease of the central nervous system presenting with significant inter- and intraindividual heterogeneity. However, the application of clinical and imaging biomarkers is currently not able to allow individual characterization and prediction. Complementary, molecular biomarkers which are easily quantifiable come from the areas of immunology and neurobiology due to the causal pathomechanisms and can excellently complement other disease characteristics. Only a few molecular biomarkers have so far been routinely used in clinical practice as their validation and transfer take a long time. This review describes the characteristics that an ideal MS biomarker should have and the challenges of establishing new biomarkers. In addition, clinically relevant and promising biomarkers from the blood and cerebrospinal fluid are presented which are useful for MS diagnosis and prognosis as well as for the assessment of therapy response and side effects.
topic Multiple sclerosis
Molecular biomarker
Oligoclonal bands
Neurofilament
Cerebrospinal fluid
Treatment response
url https://doi.org/10.1186/s12974-019-1674-2
work_keys_str_mv AT tjalfziemssen molecularbiomarkersinmultiplesclerosis
AT katjaakgun molecularbiomarkersinmultiplesclerosis
AT wolfgangbruck molecularbiomarkersinmultiplesclerosis
_version_ 1724369429679046656